Biocompatibility Testing of Medical Plastic Pellets: Standards, Test Items, and Technical Methods

Biocompatibility testing of medical plastic pellets is the essential first step in verifying that polymer raw materials intended for medical devices satisfy the biological safety requirements of the ISO 10993 series. This technical article explains the evaluation framework, sample preparation, core test items, laboratory methods, and typical applications associated with medical-grade plastic pellets. It is designed to help materials engineers, quality managers, and regulatory affairs specialists build compliant biological evaluation programs and accelerate medical device registration.

Technical Overview

Medical plastic pellets are the primary raw material form in which medical-grade polymers are supplied to device manufacturers. Before injection molding, extrusion, or blow molding converts these pellets into finished devices, the material itself must be evaluated for biological safety. Because residual monomers, catalysts, plasticizers, antioxidants, colorants, and degradation products can migrate out of the polymer matrix during patient contact, biocompatibility testing is performed to confirm that the material does not produce cytotoxic, sensitizing, irritating, thrombogenic, or systemically toxic responses.

The internationally recognized framework for this evaluation is the ISO 10993 series, which adopts a risk-based, stepwise approach combining material characterization, in vitro screening, and confirmatory in vivo testing. ISO 10993-1 defines the evaluation tests to be considered based on two key parameters:

• Contact duration: limited contact (24 hours or less), prolonged contact (24 hours to 30 days), or permanent contact (more than 30 days)
• Contact category: surface-contacting devices (skin, mucosa, breached surface), externally communicating devices (indirect blood path, tissue or bone, circulating blood), or implant devices

In China, the equivalent national standard series is GB/T 16886, which is harmonized with ISO 10993 and is required for medical device registration. Complementary references include ASTM F748 for the selection of generic biological test methods for materials, the European adoption of the series as EN ISO 10993, and the Japanese series JIS T 0993. Modern regulatory expectations place increasing emphasis on chemical characterization of materials (ISO 10993-18) and toxicological risk assessment (ISO 10993-17) as the scientific foundation of any test program.

Testing Samples

The scope of a biocompatibility study must clearly define which material configuration is tested, because the biological response of the finished device depends on every component of the pellet formulation.

Virgin Medical-Grade Resin Pellets

Virgin pellets of the base polymer are the starting point of the evaluation. Typical medical polymers include:

• Polyvinyl chloride (PVC), rigid and plasticized, for tubing, fluid paths, and bags
• Polypropylene (PP) and polyethylene (LDPE, HDPE, UHMWPE) for syringes, vials, and orthopedic bearing surfaces
• Polycarbonate (PC) for rigid housings, luer connectors, and fluid chambers
• Thermoplastic polyurethane (TPU) for catheters and short-term implants
• Polyamide (PA) and polyether ether ketone (PEEK) for structural and implantable components
• Cycloolefin copolymer and cycloolefin polymer (COC/COP) for diagnostics and pharmaceutical packaging
• Polylactic acid (PLA), polyglycolic acid (PGA), and their copolymers (PLGA) for bioresorbable devices
• Styrenic copolymers and thermoplastic elastomers (TPE) for flexible components

Functional Compounds and Masterbatches

Functionalized compounds introduce additives that must be included in the evaluation. These include plasticizer systems for flexible PVC, antioxidant and heat-stabilizer packages, radiopaque fillers such as barium sulfate or bismuth compounds, titanium dioxide and carbon-black pigments in color masterbatches, and slip or processing aids. The compound as delivered, not only the base resin, is the true object of biological evaluation.

Molded Plaques and Extracts

Wherever possible, test articles should represent the processed state of the material, including the intended sterilization method (ethylene oxide, gamma or electron-beam irradiation, or steam). Laboratories typically prepare device-like molded plaques or test the pellets directly, then generate polar and non-polar extracts according to ISO 10993-12 for use in the biological assays.

Testing Items

ISO 10993-1 assigns test items according to the nature and duration of body contact. The following tests are the ones most frequently applied to medical plastic pellets.

Cytotoxicity (ISO 10993-5)

In vitro cytotoxicity is the universal screening test for all contact categories. It quantifies the toxic effect of material extracts or direct material contact on mammalian cell lines such as L929 mouse fibroblasts, with cell viability above 70 percent generally considered non-cytotoxic.

Sensitization (ISO 10993-10)

Sensitization testing evaluates the potential to induce delayed-type hypersensitivity, such as allergic contact dermatitis. It is required for virtually all patient-contacting materials, including those with limited skin contact.

Irritation and Intracutaneous Reactivity (ISO 10993-23)

Irritation tests assess local inflammatory responses of skin, mucosa, or eye. Intracutaneous reactivity testing in rabbits using material extracts remains the standard approach for polymer materials, while reconstructed human epidermis (RhE) in vitro models are increasingly accepted as alternatives for skin irritation.

Acute Systemic Toxicity and Pyrogenicity (ISO 10993-11)

Acute systemic toxicity testing involves single-dose administration of extracts to mice and detects leachable substances capable of causing systemic harm. Material-mediated pyrogenicity may additionally be evaluated using the rabbit pyrogen test or the in vitro monocyte activation test.

Hemocompatibility (ISO 10993-4)

For materials contacting circulating blood or the indirect blood path, evaluation covers hemolysis, thrombogenicity, coagulation, platelet activation and count, and complement activation.

Genotoxicity, Carcinogenicity, and Reproductive Toxicity (ISO 10993-3)

A standard genotoxicity battery comprises the bacterial reverse mutation (Ames) test and a mammalian chromosome-damage assay, often supplemented by an in vivo micronucleus test. Carcinogenicity and reproductive toxicity studies are generally reserved for permanent-contact implants or materials showing positive genotoxic signals.

Subacute, Subchronic, and Chronic Toxicity (ISO 10993-11)

Repeated-dose systemic studies of 14 to 90 days or longer apply mainly to materials with prolonged or permanent body contact, or when the chemical characterization reveals a toxicological concern.

Local Effects after Implantation (ISO 10993-6)

Implantation testing in rabbit paravertebral muscle or rat subcutaneous tissue, with histopathology at 1, 4, and 12 weeks or longer, evaluates the local tissue response of implant-grade pellets such as PEEK, UHMWPE, and PLGA.

Chemical Characterization and Toxicological Risk Assessment (ISO 10993-18, ISO 10993-17)

Chemical characterization identifies and quantifies extractable substances, including volatile, semi-volatile, and non-volatile organic compounds, metals, and ions. The resulting extractables and leachables profile is subjected to toxicological risk assessment against established allowable limits to justify, reduce, or extend biological testing.

Testing Methods

Sample Preparation and Extraction (ISO 10993-12)

Extraction is the critical preparatory step for all extract-based assays. Key parameters include:

• Extraction vehicles: polar media (physiological saline, cell culture medium) and non-polar media (sesame seed oil or cottonseed oil); mixed vehicles such as ethanol/saline or DMSO may be added for solubility coverage
• Extraction ratios: standardized ratios such as 0.1 g or 0.2 g of material per milliliter of vehicle on a mass basis, or 6 cm² of surface per milliliter for irregular solids
• Extraction conditions: 37 °C for 72 hours, 50 °C for 72 hours, or 70 °C for 24 hours, selected to maximize leachable yield without degrading the polymer
• Aseptic handling: extraction performed under sterile conditions for cell culture and injection assays

In Vitro Cytotoxicity (ISO 10993-5)

The extract (elution) method incubates polar and non-polar extracts with L929 fibroblasts for 24 to 48 hours and measures viability using MTT or neutral red uptake. Agar diffusion and direct contact methods apply when a molded specimen can be placed directly on the cell monolayer. Results are graded against cell morphology, the zone of lysis, and the 70 percent viability threshold.

Sensitization (ISO 10993-10)

Standard methods include the guinea pig maximization test, the Buehler closed-patch test, and the murine local lymph node assay (LLNA), which measures lymphocyte proliferation using stimulation index thresholds and is widely preferred as a reduction and refinement alternative.

Irritation (ISO 10993-23)

Rabbit intracutaneous reactivity involves injection of polar and non-polar extracts followed by scoring of erythema and edema on a 0 to 4 scale; the mean score of the test animals must not exceed that of controls by more than 1.0. In vitro skin irritation using reconstructed human epidermis models is an accepted alternative when validity criteria are met.

Systemic Toxicity and Pyrogenicity (ISO 10993-11)

Acute systemic toxicity uses a single intravenous or intraperitoneal administration of extracts to mice with observation for 72 hours. Material-mediated pyrogenicity is evaluated by rabbit pyrogen testing or the monocyte activation test as appropriate.

Hemocompatibility (ISO 10993-4)

• Hemolysis: direct-contact and extract protocols, with the hemolysis index typically required to remain below 5 percent
• Coagulation: activated partial thromboplastin time (APTT) and prothrombin time (PT)
• Platelets: platelet count and activation markers
• Complement activation: quantification of C3a, C5a, and SC5b-9 by immunoassay
• Thrombogenicity: dynamic flow-loop or static clotting-time comparison against recognized reference materials

Genotoxicity (ISO 10993-3)

The battery typically includes the bacterial reverse mutation test in several strains of Salmonella typhimurium and Escherichia coli with and without metabolic activation, an in vitro mammalian chromosomal aberration or mouse lymphoma assay, and an in vivo micronucleus test when the in vitro results are positive or inconclusive.

Chemical Characterization (ISO 10993-18)

• GC-MS and headspace GC-MS for volatile and semi-volatile organic compounds
• LC-MS/MS for non-volatile and thermally labile compounds
• ICP-MS or ICP-OES for elemental impurities, metal catalysts, and colorant residues
• Ion chromatography for anionic and cationic leachables
• FTIR, DSC, and TGA for polymer identity, composition, and thermal behavior
• Simulated-use leachables studies under clinically relevant extraction conditions

Applications

Biocompatibility data packages for medical plastic pellets support material qualification across nearly every device category:

• Injection and infusion devices: syringe barrels and plungers, needle hubs, infusion sets, three-way stopcocks, and IV cannulas
• Extruded tubing and catheters: PVC and TPU fluid paths, central venous and urinary catheters, and enteral feeding tubes
• Respiratory and anesthesia products: breathing circuits, mask bodies, humidifier chambers, and filter housings
• Laboratory and diagnostic consumables: petri dishes, pipette tips, microfluidic cartridges, and reaction vessels in COC, COP, or PP
• Implantable components: PEEK spinal and trauma implants, UHMWPE bearing surfaces, and PLA or PLGA resorbable fixation devices
• Pharmaceutical packaging and drug delivery: prefilled syringe components, vials, closures, inhaler bodies, and autoinjector housings
• Surgical instruments and barriers: instrument handles, trocars, and film-based drape materials

Pellet-level biocompatibility reports are also widely used in supplier qualification, design change control, and regulatory submissions, including technical documentation under the EU Medical Device Regulation and US premarket notification programs.

FAQ

Which tests are required for pellets with body contact of 24 hours or less?

For limited-duration surface or externally communicating contact, the baseline set is cytotoxicity (ISO 10993-5), sensitization (ISO 10993-10), and irritation or intracutaneous reactivity (ISO 10993-23). Regulators increasingly expect supporting chemical characterization per ISO 10993-18, and blood-contacting applications add hemocompatibility tests per ISO 10993-4.

Can pellet-level testing replace testing of the finished device?

No. Pellet data demonstrate material safety and support supplier qualification, but the finished device must be evaluated in its final, sterilized, and packaged form. Molding parameters, secondary processing, sterilization effects such as ethylene oxide residues or irradiation-induced degradation, and assembly adhesives can all alter the extractables profile.

How long do the tests take?

Cytotoxicity typically requires two to three weeks; irritation and acute systemic toxicity three to four weeks; sensitization six to eight weeks for the guinea pig maximization test or three to four weeks for the local lymph node assay; genotoxicity eight to twelve weeks; and implantation studies several months for long-term endpoints. A complete panel for a new material commonly takes three to six months at an accredited third-party laboratory.

Why must both polar and non-polar extracts be tested?

Leachables differ widely in polarity. Salts, ions, and polar oligomers migrate into saline, while plasticizers, lubricants, and non-polar oligomers partition into oil. Testing both vehicles, as required by ISO 10993-12, ensures the biological assays are exposed to the full spectrum of extractable substances.

What is the difference between extractables and leachables studies?

Extractables are substances released under exaggerated laboratory conditions using aggressive solvents and elevated temperatures, while leachables are substances released under simulated clinical use. Extractables data from ISO 10993-18 characterization feed the toxicological risk assessment, and leachables studies confirm actual patient exposure.

How often should biocompatibility be retested?

Retesting or documented re-evaluation is required when the material formulation, supplier, manufacturing process, or sterilization method changes, or when new toxicological knowledge emerges. A gap analysis and risk assessment conducted under ISO 10993-1 and the risk management standard ISO 14971 determine whether additional testing is necessary.